The poster presentation highlighted H2Stem®’s therapeutic potential as a valuable addition to Promethera®’s pipeline in liver-directed cell therapies.
“The preclinical results we have generated so far with H2Stem® demonstrate that these hepatobiliary progenitor cells, isolated from human livers, have the ability to engraft and repopulate rodent livers and exhibit hepatic functionality in vivo,” commented Etienne Sokal, MD, PhD, Chief Innovation and Scientific Officer of Promethera®. “At Promethera®, we are committed to bringing innovation to the treatment of severe liver diseases and other indications through novel cell-based approaches. H2Stem® strengthens our portfolio with its potential to provide an effective, safe and cost-effective treatment option for patients with severe liver diseases.”
In the study, H2Stem® cells were isolated from human liver tissue and successfully differentiated into hepatocyte-like cells in culture, demonstrated through the characterization of liver-specific markers and morphology. The data also showed that H2Stem® cells were able to grow in a 3D culture setting and exhibited hepatic functionality based on Cytochrome P450 3A4 activity and other markers for liver cell function. In a humanized liver mouse model (FRG model) with induced liver damage, H2Stem® cells were able to repopulate the liver following intrasplenic injection and differentiate into functional liver cells as indicated by the secretion of human Albumin into the mice blood and other important markers of liver cell function. Overall, the preclinical data confirmed H2Stem®’s potential as a candidate for liver cell therapy and an alternative to liver transplantation in severe liver diseases.
The poster “Human hepatobiliary progenitor cells as new candidates for liver cell therapy” presented at the EASL International Liver Congress is available on the Company’s website under “Scientific Publications”.